Y-mAbs Therapeutics, Inc.

📍 New York, United States🗓 Founded 2015👥 110 employees💰 Last funded Aug 2015
Biotechnology Research🌐 ymabs.com
Website LinkedIn
Y-mAbs is late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The Company has a broad and advanced product pipeline, including 2 pivotal-stage product candidates - naxitamab and omburtamab - which target tumors that express GD2 and B7-H3, respectively. Our mission is to become the world leader in developing antibody-based cancer products that address clear unmet needs in pediatric oncology. With the right partnerships and collaboration, we envision expanding our capabilities to treat adults - changing the course of cancer and its outcome.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2015
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Denmark
1
Frequently asked questions
Who invested in Y-mAbs Therapeutics, Inc.?
Y-mAbs Therapeutics, Inc. has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Y-mAbs Therapeutics, Inc. last raise funding?
The most recent investment in Y-mAbs Therapeutics, Inc. recorded on gritt.io was in August 2015.
When was Y-mAbs Therapeutics, Inc. founded?
Y-mAbs Therapeutics, Inc. was founded in 2015.
What industry is Y-mAbs Therapeutics, Inc. in?
Y-mAbs Therapeutics, Inc. operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Y-mAbs Therapeutics, Inc. based?
Y-mAbs Therapeutics, Inc. is headquartered in New York, United States.